Skip to content

Curaneum 20 for Covid 19

Efficacy of Curaneum 20 as a therapy against SARS-CoV-2 (COVID 19)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/11/029166
Enrollment
200
Registered
2020-11-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A00-B99- Certain infectious and parasitic diseases

Interventions

Intervention1: Curaneum 20: In the intervention arm one drop of Curaneum 20 will be provided in patientsâ?? mouth twice daily for five days. Control Intervention1: Placebo: In the Comparator group of

Sponsors

Dr Sant Prabhudasji
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: · Age >18 years · Laboratory confirmed infection with SARS-Cov-2 · In patient admission to SARS-Cov-2 therapy · Signed informed consent

Exclusion criteria

Exclusion criteria: · Patients · Pregnant or breast-feeding · Participating in other clinical trial · Not signing informed consent

Design outcomes

Primary

MeasureTime frame
Discharge after cure or deathTimepoint: till the patient is discharged or died

Secondary

MeasureTime frame
1. Proportion of patients treated with Curaneum 20 who remain treated without inten-sive care compared to control 2. Comparing Curaneum 20 treated patients with placebo control for the period till the patient becomes Covid test negative 3. The evaluation of Curaneum 20 for any drug related adverse event Timepoint: at the time of discharge or death

Countries

India

Contacts

Public ContactArunaloke Chakrabarti

Department of Medical Microbiology, PGIMER, Chandigarh

arunaloke@hotmail.com01722755155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026